Generated by AI
Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision care, surgical care, and ophthalmic pharmaceuticals. Bausch + Lomb offers contact lenses, lens care solutions, eye drops, vitamins and supplements, and prescription therapies for a range of eye conditions. Its surgical portfolio includes intraocular lenses, ophthalmic surgical devices, and instruments used in cataract and other eye procedures. The company serves consumers, eye care professionals, and healthcare providers across international markets, supporting routine vision maintenance as well as more specialized clinical treatment. Headquartered in Vaughan, Ontario, Canada, Bausch + Lomb focuses exclusively on eye health and remains a recognized name in the medical devices and ophthalmic goods industry.
Website520 Applewood Crescent
Vaughan, ON, L4K 4B4
Canada
The latest articles about BLCO.
Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
Summary of Oct 28's posts. Generated by AI.
No summary yet.
No summary yet.
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
Summary of Oct 28's posts. Generated by AI.
Investors talking about BLCO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.